US5663180A
(en)
*
|
1983-10-29 |
1997-09-02 |
G.D. Searle & Co. |
Substituted cyclopentenes for the treatment of inflammation
|
US6492413B2
(en)
*
|
1993-01-15 |
2002-12-10 |
G.D. Searle & Co. |
3.4-diaryl thiophenes and analogs thereof having use as antiinflammatory agents
|
DK0679157T3
(da)
*
|
1993-01-15 |
1998-07-27 |
Searle & Co |
Nye 3,4-diarylthiophener og analoge deraf til anvendelse som antiinflammatoriske midler
|
GB9420616D0
(en)
*
|
1994-10-12 |
1994-11-30 |
Merck Sharp & Dohme |
Method, compositions and use
|
US6090834A
(en)
*
|
1993-05-21 |
2000-07-18 |
G.D. Searle & Co. |
Substituted oxazoles for the treatment of inflammation
|
GB9602877D0
(en)
*
|
1996-02-13 |
1996-04-10 |
Merck Frosst Canada Inc |
3,4-Diaryl-2-hydroxy-2,5- dihydrofurans as prodrugs to cox-2 inhibitors
|
US5474995A
(en)
*
|
1993-06-24 |
1995-12-12 |
Merck Frosst Canada, Inc. |
Phenyl heterocycles as cox-2 inhibitors
|
US5840746A
(en)
*
|
1993-06-24 |
1998-11-24 |
Merck Frosst Canada, Inc. |
Use of inhibitors of cyclooxygenase in the treatment of neurodegenerative diseases
|
HUT74986A
(en)
*
|
1994-01-10 |
1997-03-28 |
Merck Frosst Canada Inc |
Phenyl heterocycles as cox-2 inhibitors, pharmaceutical preparations containing them, and use of them
|
WO1996003392A1
(en)
*
|
1994-07-27 |
1996-02-08 |
G.D. Searle & Co. |
Substituted thiazoles for the treatment of inflammation
|
US5620999A
(en)
*
|
1994-07-28 |
1997-04-15 |
Weier; Richard M. |
Benzenesulfonamide subtituted imidazolyl compounds for the treatment of inflammation
|
US5616601A
(en)
*
|
1994-07-28 |
1997-04-01 |
Gd Searle & Co |
1,2-aryl and heteroaryl substituted imidazolyl compounds for the treatment of inflammation
|
US6613789B2
(en)
|
1994-07-28 |
2003-09-02 |
G. D. Searle & Co. |
Heterocyclo-substituted imidazoles for the treatment of inflammation
|
US6426360B1
(en)
*
|
1994-07-28 |
2002-07-30 |
G D Searle & Co. |
4,5-substituted imidazolyl compounds for the treatment of inflammation
|
US6239172B1
(en)
*
|
1997-04-10 |
2001-05-29 |
Nitrosystems, Inc. |
Formulations for treating disease and methods of using same
|
GB2294879A
(en)
*
|
1994-10-19 |
1996-05-15 |
Merck & Co Inc |
Cylcooxygenase-2 Inhibitors
|
WO1996013483A1
(en)
*
|
1994-10-27 |
1996-05-09 |
Merck Frosst Canada Inc. |
Stilbene derivatives useful as cyclooxygenase-2 inhibitors
|
JP2636819B2
(ja)
|
1994-12-20 |
1997-07-30 |
日本たばこ産業株式会社 |
オキサゾール系複素環式芳香族化合物
|
AU702591B2
(en)
*
|
1994-12-21 |
1999-02-25 |
Merck Frosst Canada Ltd. |
Diaryl-2-(5H)-furanones as cox-2 inhibitors
|
US5633272A
(en)
*
|
1995-02-13 |
1997-05-27 |
Talley; John J. |
Substituted isoxazoles for the treatment of inflammation
|
ES2183935T3
(es)
*
|
1995-02-13 |
2003-04-01 |
Searle & Co |
Isoxazoles sustituidos para el tratamiento de la inflamacion.
|
US5691374A
(en)
*
|
1995-05-18 |
1997-11-25 |
Merck Frosst Canada Inc. |
Diaryl-5-oxygenated-2-(5H) -furanones as COX-2 inhibitors
|
WO1996038418A1
(en)
|
1995-06-02 |
1996-12-05 |
G.D. Searle & Co. |
Heterocyclo substituted hydroxamic acid derivatives as cyclooxygenase-2 and 5-lipoxygenase inhibitors
|
US6515014B2
(en)
|
1995-06-02 |
2003-02-04 |
G. D. Searle & Co. |
Thiophene substituted hydroxamic acid derivatives as cyclooxygenase-2 and 5-lipoxygenase inhibitors
|
US5643933A
(en)
*
|
1995-06-02 |
1997-07-01 |
G. D. Searle & Co. |
Substituted sulfonylphenylheterocycles as cyclooxygenase-2 and 5-lipoxygenase inhibitors
|
US6512121B2
(en)
|
1998-09-14 |
2003-01-28 |
G.D. Searle & Co. |
Heterocyclo substituted hydroxamic acid derivatives as cyclooxygenase-2 and 5-lipoxygenase inhibitors
|
US6156776A
(en)
*
|
1995-06-08 |
2000-12-05 |
Yu; Dingwei Tim |
Diaryl substituted thiazoles useful in the treatment of fungal infections
|
US5700816A
(en)
*
|
1995-06-12 |
1997-12-23 |
Isakson; Peter C. |
Treatment of inflammation and inflammation-related disorders with a combination of a cyclooxygenase-2 inhibitor and a leukotriene A4 hydrolase inhibitor
|
ATE301457T1
(de)
*
|
1995-06-12 |
2005-08-15 |
Searle & Co |
Mittel, enthaltend einen cyclooxygenase-2 inhibitor und einen 5-lipoxygenase inhibitor
|
WO1996041645A1
(en)
*
|
1995-06-12 |
1996-12-27 |
G.D. Searle & Co. |
Combination of a cyclooxygenase-2 inhibitor and a leukotriene b4 receptor antagonist for the treatment of inflammations
|
US6593361B2
(en)
|
1995-07-19 |
2003-07-15 |
Merck & Co Inc |
Method of treating colonic adenomas
|
US5968974A
(en)
*
|
1995-07-19 |
1999-10-19 |
Merck & Co., Inc. |
Method of treating colonic adenomas
|
US5837719A
(en)
*
|
1995-08-10 |
1998-11-17 |
Merck & Co., Inc. |
2,5-substituted aryl pyrroles, compositions containing such compounds and methods of use
|
US5792778A
(en)
*
|
1995-08-10 |
1998-08-11 |
Merck & Co., Inc. |
2-substituted aryl pyrroles, compositions containing such compounds and methods of use
|
US5786515A
(en)
*
|
1995-09-15 |
1998-07-28 |
Merck & Co., Inc. |
Synthesis of α-chloro or fluoro ketones
|
EP0853481A1
(de)
*
|
1995-09-27 |
1998-07-22 |
Merck Frosst Canada Inc. |
Zusammensetzungen zur behandlung von entzündungen, die gewisse prostaglandine und ein cyclooxygenase-2 hemmer enthalten
|
US5717100A
(en)
*
|
1995-10-06 |
1998-02-10 |
Merck & Co., Inc. |
Substituted imidazoles having anti-cancer and cytokine inhibitory activity
|
US6083949A
(en)
*
|
1995-10-06 |
2000-07-04 |
Merck & Co., Inc. |
Substituted imidazoles having anti-cancer and cytokine inhibitory activity
|
UA57002C2
(uk)
*
|
1995-10-13 |
2003-06-16 |
Мерк Фросст Кенада Енд Ко./Мерк Фросст Кенада Енд Сі. |
Похідне (метилсульфоніл)феніл-2-(5н)-фуранону, фармацевтична композиція та спосіб лікування
|
US5981576A
(en)
*
|
1995-10-13 |
1999-11-09 |
Merck Frosst Canada, Inc. |
(Methylsulfonyl)phenyl-2-(5H)-furanones as COX-2 inhibitors
|
US6020343A
(en)
*
|
1995-10-13 |
2000-02-01 |
Merck Frosst Canada, Inc. |
(Methylsulfonyl)phenyl-2-(5H)-furanones as COX-2 inhibitors
|
NZ322674A
(en)
*
|
1995-10-17 |
1999-08-30 |
Searle & Co |
Method of detecting cyclooxygenase-2
|
WO1997016435A1
(en)
*
|
1995-10-30 |
1997-05-09 |
Merck Frosst Canada Inc. |
3,4-diaryl-2-hydroxy-2,5-dihydrofurans as prodrugs to cox-2 inhibitors
|
US6222048B1
(en)
*
|
1995-12-18 |
2001-04-24 |
Merck Frosst Canada & Co. |
Diaryl-2-(5H)-furanones as Cox-2 inhibitors
|
ES2197983T3
(es)
*
|
1996-01-26 |
2004-01-16 |
G.D. SEARLE & CO. |
Imidazoles sustituidos con heterociclo para el tratamiento de la inflamacion.
|
HUP9902119A3
(en)
*
|
1996-02-01 |
2001-08-28 |
Merck Frosst Canada & Co Kirkl |
Diphenyl stilbene derivatives as cox-2 inhibitors and pharmaceutical compositions of the same
|
US5733909A
(en)
*
|
1996-02-01 |
1998-03-31 |
Merck Frosst Canada, Inc. |
Diphenyl stilbenes as prodrugs to COX-2 inhibitors
|
US5789413A
(en)
*
|
1996-02-01 |
1998-08-04 |
Merck Frosst Canada, Inc. |
Alkylated styrenes as prodrugs to COX-2 inhibitors
|
EP0882016B1
(de)
*
|
1996-02-01 |
2000-05-31 |
Merck Frosst Canada & Co. |
Alkylierte styrole als prodrugs zu cox-2-inhibitoren
|
PT888127E
(pt)
|
1996-02-13 |
2002-05-31 |
Searle & Co |
Combinacoes tendo efeitos imunossupresores contendo inibidores de cilcooxigenase-2 e inibidores de 5-lipoxigenase
|
EP0880363B1
(de)
|
1996-02-13 |
2002-09-11 |
G.D. SEARLE & CO. |
Arzneimittelkombinationen mit immunosuppressiven wirkungen welche cyclooxygenase-2 inhibitoren und leukotrien lta4 hydrase-inhibitoren enthalten
|
ES2243978T3
(es)
*
|
1996-02-13 |
2005-12-01 |
G.D. SEARLE & CO. |
Composiciones que comprenden un inhibidor de la ciclooxigenasa-2 y un antagonista del receptor de leucotrieno b4.
|
HUP9902645A3
(en)
*
|
1996-03-18 |
1999-12-28 |
Eisai Co Ltd |
Fused-ring carboxylic acid derivatives
|
DE69715173T2
(de)
*
|
1996-03-29 |
2003-05-08 |
Merck Frosst Canada Inc |
Bisarylcyclobutenderivate als cyclooxygenasehemmer
|
US6180651B1
(en)
|
1996-04-04 |
2001-01-30 |
Bristol-Myers Squibb |
Diarylmethylidenefuran derivatives, processes for their preparation and their uses in therapeutics
|
US5807873A
(en)
*
|
1996-04-04 |
1998-09-15 |
Laboratories Upsa |
Diarylmethylidenefuran derivatives and their uses in therapeutics
|
FR2747123B1
(fr)
*
|
1996-04-04 |
1998-06-26 |
Union Pharma Scient Appl |
Nouveaux derives diarylmethylidene tetrahydrofurane, leurs procedes de preparation, et leurs utilisations en therapeutique
|
US5908858A
(en)
|
1996-04-05 |
1999-06-01 |
Sankyo Company, Limited |
1,2-diphenylpyrrole derivatives, their preparation and their therapeutic uses
|
DE69719496T2
(de)
|
1996-04-12 |
2004-04-08 |
G.D. Searle & Co., Chicago |
N-[[4-(5-METHYL-3-PHENYLISOXAZOL-4-YL]PHENYL]SULPHONYLPROPYLAMID und sein NATRIUMSALZ ALS PRO-PHARMAKON VON COX-2 INHIBITOREN
|
US5922742A
(en)
*
|
1996-04-23 |
1999-07-13 |
Merck Frosst Canada |
Pyridinyl-2-cyclopenten-1-ones as selective cyclooxygenase-2 inhibitors
|
AU709609B2
(en)
*
|
1996-04-23 |
1999-09-02 |
Merck Frosst Canada & Co. |
Pyridinyl-2-cyclopenten-1-ones as selective cyclooxygenase-2 inhibitors
|
AU775030B2
(en)
*
|
1996-05-17 |
2004-07-15 |
Merck Frosst Company |
Compositions for a once a day treatment of cyclooxygenase-2 mediated diseases
|
CA2254121A1
(en)
*
|
1996-05-17 |
1997-11-27 |
Bruno Hancock |
Compositions for a once a day treatment of cyclooxygenase-2 mediated diseases
|
CN1140267C
(zh)
*
|
1996-05-17 |
2004-03-03 |
麦克公司 |
治疗环加氧酶-2介导的疾病的每天一次的组合物
|
US6677364B2
(en)
|
1998-04-20 |
2004-01-13 |
G.D. Searle & Co. |
Substituted sulfonylphenylheterocycles as cyclooxygenase-2 and 5-lipoxygenase inhibitors
|
US5883267A
(en)
*
|
1996-05-31 |
1999-03-16 |
Merck & Co., Inc. |
Process for making phenyl heterocycles useful as cox-2 inhibitors
|
HRP970289A2
(en)
*
|
1996-05-31 |
1998-04-30 |
Merck & Co Inc |
Process for preparing phenyl heterocycles useful as cox-2 inhibitors
|
EP0906307B1
(de)
*
|
1996-06-10 |
2005-04-27 |
Merck & Co., Inc. |
Substituierte imidazole mit cytokinin-inhibirender wirkung
|
GB9615867D0
(en)
*
|
1996-07-03 |
1996-09-11 |
Merck & Co Inc |
Process of preparing phenyl heterocycles useful as cox-2 inhibitors
|
US5677318A
(en)
*
|
1996-07-11 |
1997-10-14 |
Merck Frosst Canada, Inc. |
Diphenyl-1,2-3-thiadiazoles as anti-inflammatory agents
|
ES2188971T3
(es)
*
|
1996-08-14 |
2003-07-01 |
Searle & Co |
Forma cristalina de la 4-(5-metil-3-fenilisoxazol-4-il)benzensulfonamida.
|
US6586458B1
(en)
*
|
1996-08-16 |
2003-07-01 |
Pozen Inc. |
Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs
|
US8022095B2
(en)
*
|
1996-08-16 |
2011-09-20 |
Pozen, Inc. |
Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs
|
US5939069A
(en)
*
|
1996-08-23 |
1999-08-17 |
University Of Florida |
Materials and methods for detection and treatment of immune system dysfunctions
|
FR2753449B1
(fr)
*
|
1996-09-13 |
1998-12-04 |
Union Pharma Scient Appl |
Nouveaux derives 3,4-diaryloxazolone, leurs procedes de preparation, et leurs utilisations en therapeutique
|
WO1998016227A1
(en)
|
1996-10-15 |
1998-04-23 |
G.D. Searle & Co. |
Method of using cyclooxygenase-2 inhibitors in the treatment and prevention of neoplasia
|
US5776954A
(en)
*
|
1996-10-30 |
1998-07-07 |
Merck & Co., Inc. |
Substituted pyridyl pyrroles, compositions containing such compounds and methods of use
|
US5985930A
(en)
|
1996-11-21 |
1999-11-16 |
Pasinetti; Giulio M. |
Treatment of neurodegenerative conditions with nimesulide
|
DK0946507T3
(da)
*
|
1996-12-10 |
2004-01-26 |
Searle & Co |
Substituerede pyrrolylforbindelser til behandling af inflammation
|
EP0863134A1
(de)
*
|
1997-03-07 |
1998-09-09 |
Merck Frosst Canada Inc. |
2-(3,5-difluorophenyl)-3-(4-methylsulfonylphenyl)-2-cyclopenten-1-on zur Verwendung als Inhibitor der Cyclooxygenase-2
|
CA2283399C
(en)
*
|
1997-03-14 |
2006-02-21 |
Merck Frosst Canada & Co. |
Pyridazinones as inhibitors of cyclooxygenase-2
|
US6004960A
(en)
*
|
1997-03-14 |
1999-12-21 |
Merck Frosst Canada, Inc. |
Pyridazinones as inhibitors of cyclooxygenase-2
|
ATE244232T1
(de)
*
|
1997-03-14 |
2003-07-15 |
Merck Frosst Canada Inc |
(methylsulfonyl)phenyl-2-(5h)-furanone mit sauerstoff-bindung als cox-2-hemmer
|
US6071954A
(en)
*
|
1997-03-14 |
2000-06-06 |
Merk Frosst Canada, Inc. |
(methylsulfonyl)phenyl-2-(5H)-furanones with oxygen link as COX-2 inhibitors
|
TW492959B
(en)
*
|
1997-04-18 |
2002-07-01 |
Merck & Co Inc |
Process for making 2-aryl-3-aryl-5-halo pyridines useful as cox-2 inhibitors
|
US6130334A
(en)
*
|
1998-04-15 |
2000-10-10 |
Merck & Co., Inc. |
Process for making 2-aryl-3-aryl-5-halo pyridines useful as COX-2 inhibitors
|
US6127545A
(en)
*
|
1997-04-18 |
2000-10-03 |
Merck & Co., Inc. |
Process for making 2-aryl-3-aryl-5-halo pyridines useful as COX-2 inhibitors
|
US20040072889A1
(en)
*
|
1997-04-21 |
2004-04-15 |
Pharmacia Corporation |
Method of using a COX-2 inhibitor and an alkylating-type antineoplastic agent as a combination therapy in the treatment of neoplasia
|
US6525053B1
(en)
|
1997-08-22 |
2003-02-25 |
Abbott Laboratories |
Prostaglandin endoperoxide H synthase biosynthesis inhibitors
|
US6307047B1
(en)
*
|
1997-08-22 |
2001-10-23 |
Abbott Laboratories |
Prostaglandin endoperoxide H synthase biosynthesis inhibitors
|
KR100382619B1
(ko)
*
|
1997-09-05 |
2003-05-09 |
글락소 그룹 리미티드 |
2,3-디아릴-피라졸로[1,5-b]피리다진 유도체, 그의 제조방법 및 시클로옥시게나제 2(cox-2) 억제제로서의 용도
|
DE69829861T2
(de)
*
|
1997-09-12 |
2006-03-02 |
Merck Frosst Canada & Co, Kirkland |
2-aminopyridine als inhibitoren von cyclooxygenase-2
|
US6004950A
(en)
*
|
1997-09-12 |
1999-12-21 |
Merck Frosst Canada, Inc. |
2-aminopyridines as inhibitors of cyclooxygenase-2
|
RS49982B
(sr)
*
|
1997-09-17 |
2008-09-29 |
Euro-Celtique S.A., |
Sinergistička analgetička kombinacija analgetičkog opijata i inhibitora ciklooksigenaze-2
|
US6034089A
(en)
*
|
1997-10-03 |
2000-03-07 |
Merck & Co., Inc. |
Aryl thiophene derivatives as PDE IV inhibitors
|
US6020339A
(en)
*
|
1997-10-03 |
2000-02-01 |
Merck & Co., Inc. |
Aryl furan derivatives as PDE IV inhibitors
|
FR2769311B1
(fr)
*
|
1997-10-07 |
1999-12-24 |
Union Pharma Scient Appl |
Nouveaux derives 3,4-diarylthiazolin-2-one ou -2-thione, leurs procedes de preparation et leurs utilisations en therapeutique
|
US5972986A
(en)
*
|
1997-10-14 |
1999-10-26 |
G.D. Searle & Co. |
Method of using cyclooxygenase-2 inhibitors in the treatment and prevention of neoplasia
|
US6080876A
(en)
*
|
1997-10-29 |
2000-06-27 |
Merck & Co., Inc. |
Process for making phenyl heterocycles useful as COX-2 inhibitors
|
CA2307853A1
(en)
*
|
1997-10-30 |
1999-05-14 |
Merck Frosst Canada & Co. |
Diaryl-5-alkyl-5-methyl-2(5h)-furanones as selective cyclooxygenase-2 inhibitors
|
US6133292A
(en)
*
|
1997-10-30 |
2000-10-17 |
Merck Frosst Canada & Co. |
Diaryl-5-alkyl-5-methyl-2-(5H)-furanones as selective cyclooxygenase-2-inhibitors
|
CA2308639A1
(en)
*
|
1997-10-31 |
1999-05-14 |
G.D. Searle & Co. |
Method of using cyclooxygenase-2 inhibitors in maintaining the fetal ductus ateriosus during treatment and prevention of preterm labor
|
US6025353A
(en)
*
|
1997-11-19 |
2000-02-15 |
G.D. Searle & Co. |
Method of using cyclooxygenase-2 inhibitors as anti-angiogenic agents
|
WO1999030721A1
(en)
|
1997-12-17 |
1999-06-24 |
Cornell Research Foundation, Inc. |
Cyclooxygenase-2 inhibition
|
US7041694B1
(en)
|
1997-12-17 |
2006-05-09 |
Cornell Research Foundation, Inc. |
Cyclooxygenase-2 inhibition
|
SI2266564T1
(sl)
|
1997-12-22 |
2013-07-31 |
Euro-Celtique S.A. |
Farmacevtska oralna dozirna oblika, ki vsebuje kombinacijo opioidnega agonista in opioidnega antagonista
|
US6375957B1
(en)
|
1997-12-22 |
2002-04-23 |
Euro-Celtique, S.A. |
Opioid agonist/opioid antagonist/acetaminophen combinations
|
US6887893B1
(en)
*
|
1997-12-24 |
2005-05-03 |
Sankyo Company, Limited |
Methods and compositions for treatment and prevention of tumors, tumor-related disorders and cachexia
|
FR2775477B1
(fr)
*
|
1998-02-27 |
2000-05-19 |
Union Pharma Scient Appl |
Nouveaux derives diarylmethylene heterocycliques, leurs procedes de preparation et leurs utilisations en therapeutique
|
US6136804A
(en)
*
|
1998-03-13 |
2000-10-24 |
Merck & Co., Inc. |
Combination therapy for treating, preventing, or reducing the risks associated with acute coronary ischemic syndrome and related conditions
|
US6294558B1
(en)
|
1999-05-31 |
2001-09-25 |
Pfizer Inc. |
Sulfonylbenzene compounds as anti-inflammatory/analgesic agents
|
US6727238B2
(en)
*
|
1998-06-11 |
2004-04-27 |
Pfizer Inc. |
Sulfonylbenzene compounds as anti-inflammatory/analgesic agents
|
TNSN99111A1
(fr)
*
|
1998-06-11 |
2005-11-10 |
Pfizer |
Derives de sulfonylbenzene nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant.
|
AU754719B2
(en)
*
|
1998-08-31 |
2002-11-21 |
Merck & Co., Inc. |
Method of treating neurodegenerative diseases
|
DE19842833B4
(de)
*
|
1998-09-18 |
2005-04-14 |
Merckle Gmbh |
2-Arylalkylthio-imidazole, 2-Arylalkenylthio-imidazole und 2-Arylalkinylthio-imidazole als Entzündungs-Hemmstoffe und Hemmstoffe der Cytokin-Freisetzung
|
EP1124798A4
(de)
*
|
1998-10-27 |
2002-08-28 |
Merck & Co Inc |
Synthese von methylthiophenyl-hydroxyketonen
|
WO2000025779A1
(en)
*
|
1998-11-02 |
2000-05-11 |
Merck & Co., Inc. |
Method of treating migraines and pharmaceutical compositions
|
ES2228127T3
(es)
|
1998-11-03 |
2005-04-01 |
Glaxo Group Limited |
Derivados de pirazolopiridina como inhibidores selectivos de cox-2.
|
SA99191255B1
(ar)
|
1998-11-30 |
2006-11-25 |
جي دي سيرل اند كو |
مركبات سيليكوكسيب celecoxib
|
US6649645B1
(en)
*
|
1998-12-23 |
2003-11-18 |
Pharmacia Corporation |
Combination therapy of radiation and a COX-2 inhibitor for treatment of neoplasia
|
US20030013739A1
(en)
*
|
1998-12-23 |
2003-01-16 |
Pharmacia Corporation |
Methods of using a combination of cyclooxygenase-2 selective inhibitors and thalidomide for the treatment of neoplasia
|
US20040122011A1
(en)
*
|
1998-12-23 |
2004-06-24 |
Pharmacia Corporation |
Method of using a COX-2 inhibitor and a TACE inhibitors as a combination therapy
|
US6155267A
(en)
*
|
1998-12-31 |
2000-12-05 |
Medtronic, Inc. |
Implantable medical device monitoring method and system regarding same
|
DE60041808D1
(de)
*
|
1999-01-27 |
2009-04-30 |
Cornell Res Foundation Inc |
Behandlung von mit her-2/neu-überexprimierung einhergehendem krebs
|
WO2000052008A1
(en)
|
1999-02-27 |
2000-09-08 |
Glaxo Group Limited |
Pyrazolopyridines
|
US20010000178A1
(en)
|
1999-03-25 |
2001-04-05 |
Yu Dingwei Tim |
Pyridyl substituted thiazoles
|
US6492416B1
(en)
*
|
1999-04-14 |
2002-12-10 |
Pacific Corporation |
4,5-diaryl-3(2H)-furanone derivatives as cyclooxygenase-2 inhibitors
|
KR20010094161A
(ko)
*
|
2000-04-04 |
2001-10-31 |
서경배 |
2,2-디메틸-4,5-디아릴-3(2h)퓨라논의 유도체 및 이를함유하는 선택적인 시클로옥시게네이즈-2 저해제로서약제학적 조성물
|
IL136025A0
(en)
*
|
1999-05-14 |
2001-05-20 |
Pfizer Prod Inc |
Combination therapy for the treatment of migraine
|
CO5190664A1
(es)
|
1999-06-30 |
2002-08-29 |
Pfizer Prod Inc |
Terapia de combinacion para el tratamiento de migrana administracion de un receptor 5ht, cafeina y un inhibidor de ciclooxigenasa-2
|
US6066667A
(en)
*
|
1999-08-17 |
2000-05-23 |
Ashbrook; Charles D. |
Substituted furanones, compositions and antiarthritic use
|
WO2001017996A1
(en)
*
|
1999-09-08 |
2001-03-15 |
Merck Frosst Canada & Co. |
1,2,3-thiadiazoles and their use as cox-2 inhibitors
|
US6376242B1
(en)
*
|
1999-09-21 |
2002-04-23 |
Emory University |
Methods and compositions for treating platelet-related disorders using MPL pathway inhibitory agents
|
ATE432269T1
(de)
*
|
1999-10-08 |
2009-06-15 |
Merial Sas |
Polymorphe form b von 3-(cyclopropylmethoxy)-4- 4-(methylsulfonyl)phe yl -5,5-dimethyl-5h-furan-2- on
|
EP1099695A1
(de)
|
1999-11-09 |
2001-05-16 |
Laboratoire Theramex S.A. |
5-Aryl-1H-1,2,4-triazolverbindungen als Cyclooxygenase-2 Inhibitoren und diese enthaltende pharmazeutische Zusammensetzungen
|
DK1104760T3
(da)
|
1999-12-03 |
2003-06-30 |
Pfizer Prod Inc |
Sulfamoylheteroarylpyrazolforbindelser som anti-inflammatoriske/analgetiske midler
|
PT1104758E
(pt)
|
1999-12-03 |
2003-12-31 |
Pfizer Prod Inc |
Derivados de acetileno como agentes anti-inflamatorios/analgesicos
|
KR20020058074A
(ko)
|
1999-12-03 |
2002-07-12 |
데이비드 존 우드 |
소염진통제로서의 헤테로시클로-알킬술포닐 피라졸 유도체
|
EP1104759B1
(de)
|
1999-12-03 |
2003-10-22 |
Pfizer Products Inc. |
Heteroarylphenylpyrazolverbindungen zur Verwendung als analgetisches/entzündungshemmendes Mittel
|
UA74539C2
(en)
|
1999-12-08 |
2006-01-16 |
Pharmacia Corp |
Crystalline polymorphous forms of celecoxib (variants), a method for the preparation thereof (variants), a pharmaceutical composition (variants)
|
BR0008060A
(pt)
|
1999-12-08 |
2002-02-05 |
Pharmacia Corp |
Composições inibidoras de ciclooxigenase-2 tendo rápido inìcio de eficácia terapêutica
|
CN1216869C
(zh)
*
|
1999-12-08 |
2005-08-31 |
药品公司 |
赛利可喜的多态晶型
|
GB9930358D0
(en)
|
1999-12-22 |
2000-02-09 |
Glaxo Group Ltd |
Process for the preparation of chemical compounds
|
NZ519781A
(en)
*
|
1999-12-23 |
2004-04-30 |
Nitromed Inc |
Nitrosated and nitrosylated cyclooxygenase-2 inhibitors, compositions and methods of use
|
DE10001166A1
(de)
|
2000-01-13 |
2001-07-19 |
Merckle Gmbh |
Anellierte Pyrrolverbindungen, diese enthaltende pharmazeutische Mittel und deren Verwendung
|
ES2328446T5
(es)
|
2000-02-04 |
2014-02-27 |
Children's Hospital Research Foundation |
Uso de lipasa ácida lisosomal para tratar la aterosclerosis y enfermedades asociadas
|
DE60135441D1
(de)
|
2000-02-08 |
2008-10-02 |
Euro Celtique Sa |
Zusammensetzungen mit kontrollierter freisetzung, die einen opioid agonist und antagonist enthalten
|
SI1299104T1
(sl)
|
2000-02-08 |
2009-10-31 |
Euro Celtique Sa |
Oralne formulacije opioidnih agonistov, varne pred zlorabo
|
EP1296971A2
(de)
*
|
2000-04-25 |
2003-04-02 |
Pharmacia Corporation |
2-fluorobenzolsulfonyl-derivate zur behandlung von entzündungen
|
ES2166710B1
(es)
*
|
2000-04-25 |
2004-10-16 |
J. URIACH & CIA, S.A. |
Nuevos compuestos heterociclicos con actividad antiinflamatoria.
|
CN1443180A
(zh)
*
|
2000-05-22 |
2003-09-17 |
雷迪实验室有限公司 |
具有抗炎活性的新的化合物:它们的制备方法和含有它们的药物组合物
|
BR0111767A
(pt)
|
2000-06-13 |
2003-07-08 |
Wyeth Corp |
Composições analgésicas e anti-inflamatórias contendo inibidores de cox-2, seu uso e método para potencializar um composto analgésico
|
US6465509B2
(en)
*
|
2000-06-30 |
2002-10-15 |
Merck Frosst Canada & Co. |
Pyrones as inhibitors of cyclooxygenase-2
|
AU5754701A
(en)
*
|
2000-07-13 |
2002-01-30 |
Pharmacia Corp |
Method of using cox-2 inhibitors in the treatment and prevention of ocular cox-2mediated disorders
|
PE20020146A1
(es)
*
|
2000-07-13 |
2002-03-31 |
Upjohn Co |
Formulacion oftalmica que comprende un inhibidor de ciclooxigenasa-2 (cox-2)
|
CZ302448B6
(cs)
*
|
2000-07-20 |
2011-05-25 |
Lauras As |
Farmaceutický prostredek
|
US6716829B2
(en)
|
2000-07-27 |
2004-04-06 |
Pharmacia Corporation |
Aldosterone antagonist and cyclooxygenase-2 inhibitor combination therapy to prevent or treat inflammation-related cardiovascular disorders
|
PE20020506A1
(es)
|
2000-08-22 |
2002-07-09 |
Glaxo Group Ltd |
Derivados de pirazol fusionados como inhibidores de la proteina cinasa
|
WO2002017896A2
(en)
*
|
2000-08-29 |
2002-03-07 |
Peter Van Patten |
Combination for the treatment of migraine comprising a cyclooxygenase-2 inhibitor and acetylsalicylic acid
|
GB0021494D0
(en)
*
|
2000-09-01 |
2000-10-18 |
Glaxo Group Ltd |
Chemical comkpounds
|
US20030219461A1
(en)
*
|
2000-09-12 |
2003-11-27 |
Britten Nancy J. |
Parenteral combination therapy for infective conditions
|
WO2002022124A1
(en)
*
|
2000-09-18 |
2002-03-21 |
Merck & Co., Inc. |
Treatment of inflammation with a combination of a cyclooxygenase-2 inhibitor and an integrin alpha-v antagonist
|
DE10057366A1
(de)
*
|
2000-11-18 |
2002-05-23 |
Mahle Gmbh |
Verfahren zur gießtechnischen Herstellung eines Kolbens mit einem gekühlten Ringträger
|
WO2002048147A2
(en)
|
2000-12-15 |
2002-06-20 |
Glaxo Group Limited |
Pyrazolopyridines
|
US7163940B2
(en)
|
2000-12-15 |
2007-01-16 |
Smithkline Beecham Corporation |
Pyrazolopyridinyl pyrimidine therapeutic compounds
|
AU2002249812B2
(en)
|
2000-12-21 |
2005-11-10 |
Nicox S.A. |
Substituted aryl compounds as novel cyclooxygenase-2 selective inhibitors, compositions and methods of use
|
US7115565B2
(en)
*
|
2001-01-18 |
2006-10-03 |
Pharmacia & Upjohn Company |
Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability
|
AUPR283801A0
(en)
*
|
2001-02-01 |
2001-03-01 |
Australian National University, The |
Chemical compounds and methods
|
WO2002062391A2
(en)
*
|
2001-02-02 |
2002-08-15 |
Pharmacia Corporation |
Method of using a cyclooxygenase-2 inhibitor and sex steroids as a combination therapy for the treatment and prevention of dismenorrhea
|
DE10107683A1
(de)
|
2001-02-19 |
2002-08-29 |
Merckle Gmbh Chem Pharm Fabrik |
2-Thio-substituierte Imidazolderivate und ihre Verwendung in der Pharmazie
|
ES2227451T3
(es)
|
2001-03-08 |
2005-04-01 |
Smithkline Beecham Corporation |
Derivados de pirazolopiridina.
|
US7034030B2
(en)
|
2001-03-30 |
2006-04-25 |
Smithkline Beecham Corporation |
Pyralopyridines, process for their preparation and use as therapeutic compounds
|
US7695736B2
(en)
|
2001-04-03 |
2010-04-13 |
Pfizer Inc. |
Reconstitutable parenteral composition
|
JP4219171B2
(ja)
|
2001-04-10 |
2009-02-04 |
スミスクライン ビーチャム コーポレーション |
抗ウイルス性ピラゾロピリジン化合物
|
US20030105144A1
(en)
|
2001-04-17 |
2003-06-05 |
Ping Gao |
Stabilized oral pharmaceutical composition
|
US6673818B2
(en)
|
2001-04-20 |
2004-01-06 |
Pharmacia Corporation |
Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation
|
US6962914B2
(en)
|
2001-04-27 |
2005-11-08 |
Smithkline Beecham Corporation |
Pyrazolopyridinyl pyridine and pyrimidine therapeutic compounds
|
US6756498B2
(en)
|
2001-04-27 |
2004-06-29 |
Smithkline Beecham Corporation |
Process for the preparation of chemical compounds
|
UA81224C2
(uk)
|
2001-05-02 |
2007-12-25 |
Euro Celtic S A |
Дозована форма оксикодону та її застосування
|
US20040132780A1
(en)
*
|
2001-05-04 |
2004-07-08 |
Allen Christopher P. |
Method and compositions for treating migraines
|
EP1387673B1
(de)
|
2001-05-11 |
2010-12-29 |
Endo Pharmaceuticals Inc. |
Opioid enthaltende arzneiform gegen missbrauch
|
GB0112810D0
(en)
*
|
2001-05-25 |
2001-07-18 |
Glaxo Group Ltd |
Pyrimidine derivatives
|
GB0112802D0
(en)
*
|
2001-05-25 |
2001-07-18 |
Glaxo Group Ltd |
Pyrimidine derivatives
|
US20030153801A1
(en)
*
|
2001-05-29 |
2003-08-14 |
Pharmacia Corporation |
Compositions of cyclooxygenase-2 selective inhibitors and radiation for inhibition or prevention of cardiovascular disease
|
AP2003002922A0
(en)
*
|
2001-05-31 |
2003-12-31 |
Pharmacia Corp |
Skin-permeable selective cyclooxygenase-2 inhibitor composition.
|
DE10129320A1
(de)
*
|
2001-06-19 |
2003-04-10 |
Norbert Mueller |
Verwendung von COX-2 Inhibitoren zur Behandlung von Schizophrenie, wahnhaften Störungen, affektiven Störungen oder Ticstörungen
|
US20060167074A1
(en)
*
|
2001-06-19 |
2006-07-27 |
Norbert Muller |
Methods and compositions for the treatment of psychiatric disorders
|
WO2003000689A1
(en)
|
2001-06-21 |
2003-01-03 |
Smithkline Beecham Corporation |
Imidazo`1,2-a!pyridine derivatives for the prophylaxis and treatment of herpes viral infections
|
ES2241964T3
(es)
|
2001-07-05 |
2005-11-01 |
Pfizer Products Inc. |
Heterocicloalquilsulfufonilpirazoles como agentes antiinflamatorios/abnalgesicos.
|
SI1416842T1
(sl)
|
2001-07-18 |
2009-06-30 |
Euro Celtique Sa |
Farmacevtske kombinacije oksikodona in naloksona
|
WO2003013433A2
(en)
|
2001-08-06 |
2003-02-20 |
Euro-Celtique S.A. |
Sequestered antagonist formulations
|
DK1414451T3
(da)
|
2001-08-06 |
2009-08-10 |
Euro Celtique Sa |
Opioidagonistformuleringer med frigivelig og sekvenstreret antagonist
|
US20030044458A1
(en)
|
2001-08-06 |
2003-03-06 |
Curtis Wright |
Oral dosage form comprising a therapeutic agent and an adverse-effect agent
|
UA80682C2
(en)
*
|
2001-08-06 |
2007-10-25 |
Pharmacia Corp |
Orally deliverable stabilized oral suspension formulation and process for the incresaing physical stability of thixotropic pharmaceutical composition
|
US20030068375A1
(en)
|
2001-08-06 |
2003-04-10 |
Curtis Wright |
Pharmaceutical formulation containing gelling agent
|
GB0119477D0
(en)
*
|
2001-08-09 |
2001-10-03 |
Glaxo Group Ltd |
Pyrimidine derivatives
|
AR038957A1
(es)
|
2001-08-15 |
2005-02-02 |
Pharmacia Corp |
Terapia de combinacion para el tratamiento del cancer
|
WO2003018575A1
(en)
*
|
2001-08-24 |
2003-03-06 |
Wyeth Holdings Corporation |
5-substituted-3(2h)-furanones useful for inhibition of farnesyl-protein transferase
|
US20030236308A1
(en)
*
|
2001-09-18 |
2003-12-25 |
Pharmacia Corporation |
Compositions of cyclooxygenase-2 selective inhibitors and acetaminophen for treatment and prevention of inflammation, inflammation-mediated disorders and pain
|
US20030114483A1
(en)
*
|
2001-09-18 |
2003-06-19 |
Pharmacia Corporation |
Compositions of chromene cyclooxygenase-2 selective inhibitors and acetaminophen for treatment and prevention of inflammation, inflammation-mediated disorders and pain
|
US20030181501A1
(en)
*
|
2001-09-26 |
2003-09-25 |
Le Trang T. |
Intraorally disintegrating valdecoxib compositions
|
GT200200183A
(es)
|
2001-09-28 |
2003-05-23 |
|
Procedimiento para preparar derivados de heterocicloalquilsulfonil pirazol
|
WO2003031446A1
(en)
|
2001-10-05 |
2003-04-17 |
Smithkline Beecham Corporation |
Imidazo-pyridine derivatives for use in the treatment of herpes viral infection
|
KR100810468B1
(ko)
|
2001-10-10 |
2008-03-07 |
씨제이제일제당 (주) |
사이클로옥시게나제-2의 저해제로서 선택성이 뛰어난1h-인돌 유도체
|
KR100824233B1
(ko)
*
|
2001-10-10 |
2008-04-24 |
씨제이제일제당 (주) |
사이클로옥시게나제-2의 저해제로서 선택성이 뛰어난3,4-디하이드로-1h-나프탈렌 유도체
|
WO2003037336A1
(en)
|
2001-11-02 |
2003-05-08 |
Pfizer Products Inc. |
1-(5-sulfonyl-pyridin-2-yl)-5-(methylidene-cycloalkylmethoxy)-1h-pyrazole-4-carbonitrile derivatives and other compounds as cyclooxygenase inhibitors for the treatment of arthritis, neurodegeneration and colon cancer
|
AU2002357043B2
(en)
|
2001-12-06 |
2008-04-24 |
Merck Sharp & Dohme Corp. |
Mitotic kinesin inhibitors
|
FR2833164B1
(fr)
*
|
2001-12-07 |
2004-07-16 |
Oreal |
Compositions cosmetiques antisolaires a base d'un melange synergique de filtres et utilisations
|
ES2292839T3
(es)
|
2001-12-11 |
2008-03-16 |
Smithkline Beecham Corporation |
Derivados de pirazolo-piridina como agentes contra el herpes.
|
DE10162120A1
(de)
*
|
2001-12-12 |
2003-06-18 |
Berolina Drug Dev Ab Svedala |
Deuterierte substituierte Dihydrofuranone sowie diese Verbindungen enthaltende Arzneimittel
|
US20040082940A1
(en)
*
|
2002-10-22 |
2004-04-29 |
Michael Black |
Dermatological apparatus and method
|
US20030220374A1
(en)
*
|
2002-01-14 |
2003-11-27 |
Pharmacia Corporation |
Compositions and methods of treatment involving peroxisome proliferator-activated receptor-gamma agonists and cyclooxygenase-2 selective inhibitors
|
US20030212138A1
(en)
*
|
2002-01-14 |
2003-11-13 |
Pharmacia Corporation |
Combinations of peroxisome proliferator-activated receptor-alpha agonists and cyclooxygenase-2 selective inhibitors and therapeutic uses therefor
|
US6667330B2
(en)
|
2002-01-31 |
2003-12-23 |
Galileo Pharmaceuticals, Inc. |
Furanone derivatives
|
US7985771B2
(en)
*
|
2002-01-31 |
2011-07-26 |
Monsanto Technology Llc |
Furanone derivatives
|
DE20308437U1
(de)
|
2002-04-05 |
2003-11-13 |
Euro Celtique Sa |
Matrix zur verzögerten, gleichbleibenden und unabhängigen Freisetzung von Wirkstoffen
|
CA2481035A1
(en)
*
|
2002-04-08 |
2003-10-16 |
Glaxo Group Limited |
(2-((2-alkoxy) -phenyl) -cyclopent-1-enyl) aromatic carbo and heterocyclic acid and derivatives
|
IL164163A0
(en)
*
|
2002-04-09 |
2005-12-18 |
Pharmacia Corp |
Process for preparing a finely self-emulsifiable pharmaceutical composition
|
US7329401B2
(en)
|
2002-04-15 |
2008-02-12 |
The Regents Of The University Of California |
Cyclooxygenase-2 selective agents useful as imaging probes and related methods
|
AU2003230965B2
(en)
|
2002-04-17 |
2008-02-21 |
The Cleveland Clinic Foundation |
Systemic marker for monitoring anti-inflammatory and antioxidant actions of therapeutic agents
|
CA2484017A1
(en)
*
|
2002-04-22 |
2003-10-30 |
Pfizer Products Inc. |
Indol-2-ones as selective inhibitors of cyclooxygenase-2
|
GB0210121D0
(en)
|
2002-05-02 |
2002-06-12 |
Celltech R&D Ltd |
Biological products
|
ES2685697T3
(es)
|
2002-05-09 |
2018-10-10 |
The Brigham And Women's Hospital, Inc. |
1L1RL-1 como un marcador de enfermedades cardiovasculares
|
WO2003095623A2
(en)
*
|
2002-05-10 |
2003-11-20 |
The Trustees Of Columbia University In The City Of New York |
Genetically engineered cell lines and systems for propagating varicella zoster virus and methods of use thereof
|
KR100804827B1
(ko)
|
2002-05-17 |
2008-02-20 |
씨제이제일제당 (주) |
티아졸리딘-4-온 유도체, 그 제조방법 및 약제학적 조성물
|
US20030225054A1
(en)
*
|
2002-06-03 |
2003-12-04 |
Jingwu Duan |
Combined use of tace inhibitors and COX2 inhibitors as anti-inflammatory agents
|
KR100465455B1
(ko)
|
2002-06-24 |
2005-01-13 |
씨제이 주식회사 |
2-티옥소티아졸 유도체, 그 제조방법 및 약제학적 조성물
|
KR100478467B1
(ko)
|
2002-06-24 |
2005-03-23 |
씨제이 주식회사 |
피라졸-3-온 유도체, 그 제조방법 및 약제학적 조성물
|
WO2004002409A2
(en)
*
|
2002-06-27 |
2004-01-08 |
Nitromed, Inc. |
Cyclooxygenase-2 selective inhibitors, compositions and methods of use
|
EP1539679A4
(de)
*
|
2002-06-28 |
2007-07-04 |
Nitromed Inc |
Oxim- und/oder hydrazonhaltige, nitrosierte und/oder nitrosylierte cyclooxigenase-2-selektive inhibitoren, zusammensetzungen und anwendungsverfahren
|
AU2003248759A1
(en)
*
|
2002-07-02 |
2004-01-23 |
Pharmacia Corporation |
Use of cyclooxygenase-2 selective inhibitors and thrombolytic agents for the treatment or prevention of a vaso-occlusive event
|
US7771707B2
(en)
|
2004-06-12 |
2010-08-10 |
Collegium Pharmaceutical, Inc. |
Abuse-deterrent drug formulations
|
KR100467668B1
(ko)
|
2002-08-07 |
2005-01-24 |
씨제이 주식회사 |
1,2,4-트리아졸 유도체, 그 제조방법 및 약제학적 조성물
|
ATE325115T1
(de)
*
|
2002-08-19 |
2006-06-15 |
Glaxo Group Ltd |
Pyrimidinderivate als selektive cox-2-inhibitoren
|
DE10238045A1
(de)
|
2002-08-20 |
2004-03-04 |
Merckle Gmbh Chem.-Pharm. Fabrik |
2-Thio-substituierte Imidazolderivate und ihre Verwendung in der Pharmazie
|
UY27939A1
(es)
|
2002-08-21 |
2004-03-31 |
Glaxo Group Ltd |
Compuestos
|
GB0221443D0
(en)
|
2002-09-16 |
2002-10-23 |
Glaxo Group Ltd |
Pyridine derivates
|
AU2003270778B2
(en)
|
2002-09-20 |
2009-10-08 |
Alpharma Pharmaceuticals, Llc |
Sequestering subunit and related compositions and methods
|
US8303511B2
(en)
*
|
2002-09-26 |
2012-11-06 |
Pacesetter, Inc. |
Implantable pressure transducer system optimized for reduced thrombosis effect
|
AU2003275266A1
(en)
|
2002-10-03 |
2004-05-04 |
Smithkline Beecham Corporation |
Therapeutic compounds based on pyrazolopyridine derivatives
|
DK1556083T3
(da)
*
|
2002-10-08 |
2011-04-04 |
Rinat Neuroscience Corp |
Fremgangsmåde til behandling af post-operative smerter ved indgivelse af en antistof mod nervevækstfaktor og sammensætning indeholdende samme
|
US7255860B2
(en)
|
2002-10-08 |
2007-08-14 |
Rinat Neuroscience Corp. |
Methods for treating post-surgical pain by administering an anti-nerve growth factor antagonist antibody
|
KR100484525B1
(ko)
*
|
2002-10-15 |
2005-04-20 |
씨제이 주식회사 |
이소티아졸 유도체, 그 제조방법 및 약제학적 조성물
|
US20040082543A1
(en)
*
|
2002-10-29 |
2004-04-29 |
Pharmacia Corporation |
Compositions of cyclooxygenase-2 selective inhibitors and NMDA receptor antagonists for the treatment or prevention of neuropathic pain
|
JP2006507299A
(ja)
*
|
2002-10-30 |
2006-03-02 |
メルク エンド カムパニー インコーポレーテッド |
Akt活性の阻害薬
|
GB0225548D0
(en)
*
|
2002-11-01 |
2002-12-11 |
Glaxo Group Ltd |
Compounds
|
AU2003283096A1
(en)
*
|
2002-11-05 |
2004-06-07 |
Merck Frosst Canada And Co. |
Nitric oxide releasing prodrugs of diaryl-2-(5h)-furanones as cyclooxygenase-2 inhibitors
|
AU2003291757A1
(en)
*
|
2002-11-08 |
2004-06-03 |
Bristol-Myers Squibb Company |
Formulations of low solubility bioactive agents and processes for making the same
|
US20040147581A1
(en)
*
|
2002-11-18 |
2004-07-29 |
Pharmacia Corporation |
Method of using a Cox-2 inhibitor and a 5-HT1A receptor modulator as a combination therapy
|
KR100470075B1
(ko)
|
2002-11-21 |
2005-02-05 |
씨제이 주식회사 |
1,2,4-트리아졸 유도체, 그 제조방법 및 약제학적 조성물
|
GB0227443D0
(en)
*
|
2002-11-25 |
2002-12-31 |
Glaxo Group Ltd |
Pyrimidine derivatives
|
KR100491317B1
(ko)
|
2002-11-26 |
2005-05-24 |
씨제이 주식회사 |
1,2,4-트리아졸 유도체, 그 제조방법 및 약제학적 조성물
|
KR100470076B1
(ko)
|
2002-11-27 |
2005-02-05 |
씨제이 주식회사 |
1,2,4-트리아졸 유도체, 그 제조방법 및 약제학적 조성물
|
WO2004054560A1
(en)
|
2002-12-13 |
2004-07-01 |
Warner-Lambert Company Llc |
Alpha-2-delta ligand to treat lower urinary tract symptoms
|
BR0317539A
(pt)
*
|
2002-12-19 |
2005-11-22 |
Pharmacia Corp |
Métodos e composições para o tratamento de infecções por vìrus da herpes usando inibidores seletivos da ou ciclooxigenase-2 ou inibidores da ciclooxigenase-2 em combinação com agentes antivirais
|
US20040171664A1
(en)
*
|
2002-12-20 |
2004-09-02 |
Pharmacia Corporation |
Compositions of cyclooxygenase-2 selective inhibitors and selective serotonin reuptake inhibitors for the treatment or prevention of a vaso-occlusive event
|
ES2215474B1
(es)
*
|
2002-12-24 |
2005-12-16 |
J. URIACH & CIA S.A. |
Nuevos derivados de fosforamida.
|
US9498530B2
(en)
|
2002-12-24 |
2016-11-22 |
Rinat Neuroscience Corp. |
Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the same
|
CA2511598C
(en)
|
2002-12-24 |
2016-09-13 |
Rinat Neuroscience Corp. |
Anti-ngf antibodies and methods using same
|
US7569364B2
(en)
*
|
2002-12-24 |
2009-08-04 |
Pfizer Inc. |
Anti-NGF antibodies and methods using same
|
ATE546134T1
(de)
*
|
2002-12-26 |
2012-03-15 |
Pozen Inc |
Mehrschichtige dosierformen enthaltend naproxen und triptane
|
US7772188B2
(en)
|
2003-01-28 |
2010-08-10 |
Ironwood Pharmaceuticals, Inc. |
Methods and compositions for the treatment of gastrointestinal disorders
|
US20070265606A1
(en)
*
|
2003-02-14 |
2007-11-15 |
Reliant Technologies, Inc. |
Method and Apparatus for Fractional Light-based Treatment of Obstructive Sleep Apnea
|
CA2516454A1
(en)
|
2003-02-19 |
2004-09-02 |
Rinat Neuroscience Corp. |
Methods for treating pain by administering a nerve growth factor antagonist and an nsaid and compositions containing the same
|
US20050004098A1
(en)
*
|
2003-03-20 |
2005-01-06 |
Britten Nancy Jean |
Dispersible formulation of an anti-inflammatory agent
|
US20040214753A1
(en)
*
|
2003-03-20 |
2004-10-28 |
Britten Nancy Jean |
Dispersible pharmaceutical composition for treatment of mastitis and otic disorders
|
US20050009931A1
(en)
*
|
2003-03-20 |
2005-01-13 |
Britten Nancy Jean |
Dispersible pharmaceutical composition for treatment of mastitis and otic disorders
|
DE602004002201T2
(de)
*
|
2003-03-20 |
2007-09-20 |
Pharmacia Corp. |
Dispergierbare pharmazeutische zusammensetzung eines entzündungshemmers
|
US20040220155A1
(en)
*
|
2003-03-28 |
2004-11-04 |
Pharmacia Corporation |
Method of providing a steroid-sparing benefit with a cyclooxygenase-2 inhibitor and compositions therewith
|
MY135852A
(en)
|
2003-04-21 |
2008-07-31 |
Euro Celtique Sa |
Pharmaceutical products
|
WO2004093814A2
(en)
*
|
2003-04-22 |
2004-11-04 |
Pharmacia Corporation |
Compositions of a cyclooxygenase-2 selective inhibitor and a sodium channel blocker
|
WO2004093813A2
(en)
*
|
2003-04-22 |
2004-11-04 |
Pharmacia Corporation |
Compositions of a cyclooxygenase-2 selective inhibitor and a calcium modulating agent for the treatment of pain, inflammation or inflammation mediated disorders
|
WO2004093895A1
(en)
*
|
2003-04-22 |
2004-11-04 |
Pharmacia Corporation |
Compositions of a cyclooxygenase-2 selective inhibitor and a potassium ion channel modulator for the treatment of pain, inflammation or inflammation mediated disorders
|
US20050159403A1
(en)
*
|
2003-04-22 |
2005-07-21 |
Pharmacia Corporation |
Compositions of a cyclooxygenase-2 selective inhibitor and a calcium modulating agent for the treatment of central nervous system damage
|
WO2004100895A2
(en)
*
|
2003-05-13 |
2004-11-25 |
Pharmacia Corporation |
Compositions of a cyclooxygenase-2 selective inhibitor and a peroxisome proliferator activated receptor agonist for the treatment of ischemic mediated central nervous system disorders
|
US20060160776A1
(en)
*
|
2003-05-28 |
2006-07-20 |
Pharmacia Corporation |
Compositions of a cyclooxygenase-2 selective inhibitor and a cannabinoid agent for the treatment of central nervous system damage
|
US7923467B2
(en)
|
2003-05-30 |
2011-04-12 |
Ranbaxy Laboratories, Inc. |
Substituted pyrrole derivatives and their use as HMG-CO inhibitors
|
CN1309717C
(zh)
*
|
2003-06-03 |
2007-04-11 |
李小虎 |
4-芳基-5h-噻吩-2-酮衍生物、其制法和用途
|
WO2004110492A2
(en)
*
|
2003-06-06 |
2004-12-23 |
Glaxo Group Limited |
Composition comprising triptans and nsaids
|
WO2005000238A2
(en)
*
|
2003-06-20 |
2005-01-06 |
Merck & Co., Inc. |
Use of selective cyclooxygenase-2 inhibitors for the treatment of endometriosis
|
WO2005000297A1
(en)
*
|
2003-06-24 |
2005-01-06 |
Pharmacia Corporation |
Treatment of migraine accompanied by nausea
|
WO2005007106A2
(en)
*
|
2003-07-10 |
2005-01-27 |
Pharmacia Corporation |
Compositions of a cyclooxygenase-2 selective inhibitor and a non-nmda glutamate modulator for the treatment of central nervous system damage
|
WO2005009342A2
(en)
*
|
2003-07-16 |
2005-02-03 |
Pharmacia Corporation |
Method for the treatment or prevention of dermatological disorders with a cyclooxygenase-2 inhibitor alone and in combination with a dermatological treatment agent and compositions therewith
|
WO2005009354A2
(en)
*
|
2003-07-17 |
2005-02-03 |
Pharmacia Corporation |
Compositions of a cyclooxygenase-2 selective inhibitor and an ikk inhibitor for the treatment of ischemic-mediated central nervous system disorders or injury
|
CA2536173A1
(en)
*
|
2003-08-20 |
2005-03-03 |
Nitromed, Inc. |
Nitrosated and nitrosylated cardiovascular compounds, compositions and methods of use
|
US20050119262A1
(en)
*
|
2003-08-21 |
2005-06-02 |
Pharmacia Corporation |
Method for preventing or treating an optic neuropathy with a cox-2 inhibitor and an intraocular pressure reducing agent
|
US20050107350A1
(en)
*
|
2003-08-22 |
2005-05-19 |
Pharmacia Corporation |
Method for the treatment or prevention of bone disorders with a cyclooxygenase-2 inhibitor alone and in combination with a bone disorder treatment agent and compositions therewith
|
US20050187278A1
(en)
*
|
2003-08-28 |
2005-08-25 |
Pharmacia Corporation |
Treatment or prevention of vascular disorders with Cox-2 inhibitors in combination with cyclic AMP-specific phosphodiesterase inhibitors
|
AU2004270161A1
(en)
*
|
2003-08-28 |
2005-03-17 |
Nicox S.A. |
Nitrosated and nitrosylated cardiovascular compounds, compositions and methods of use
|
DK2384753T3
(en)
|
2003-08-29 |
2016-04-11 |
Brigham & Womens Hospital |
Hydantoin derivatives as inhibitors of cell necrosis
|
WO2005023189A2
(en)
*
|
2003-09-03 |
2005-03-17 |
Pharmacia Corporation |
Method of cox-2 selective inhibitor and nitric oxide-donating agent
|
US20050131028A1
(en)
*
|
2003-09-11 |
2005-06-16 |
Pharmacia Corporation |
Methods and compositions for the extended duration treatment of pain, inflammation and inflammation-related disorders
|
SI1663229T1
(sl)
|
2003-09-25 |
2010-08-31 |
Euro Celtique Sa |
Farmacevtske kombinacije hidrokodona in naltreksona
|
GB0323585D0
(en)
*
|
2003-10-08 |
2003-11-12 |
Glaxo Group Ltd |
Compounds
|
GB0323584D0
(en)
*
|
2003-10-08 |
2003-11-12 |
Glaxo Group Ltd |
Compounds
|
GB0323581D0
(en)
*
|
2003-10-08 |
2003-11-12 |
Glaxo Group Ltd |
Novel compounds
|
FR2860792B1
(fr)
*
|
2003-10-10 |
2006-02-24 |
Sanofi Synthelabo |
Derives de thiophene-2-carboxamide, leur preparation et leur application en therapeutique
|
WO2005044227A1
(en)
*
|
2003-11-05 |
2005-05-19 |
Glenmark Pharmaceuticals Limited |
Topical pharmaceutical compositions
|
US20050100594A1
(en)
*
|
2003-11-12 |
2005-05-12 |
Nilendu Sen |
Pharmaceutical formulation containing muscle relaxant and COX-II inhibitor
|
EP1689721B1
(de)
*
|
2003-11-26 |
2010-07-14 |
Pfizer Products Inc. |
Aminopyrazolderivate als gsk-3-inhibitoren
|
US7067159B2
(en)
*
|
2003-12-05 |
2006-06-27 |
New Chapter, Inc. |
Methods for treating prostate cancer with herbal compositions
|
CA2549236C
(en)
|
2003-12-05 |
2017-06-13 |
The Cleveland Clinic Foundation |
Risk markers for cardiovascular disease
|
US7070816B2
(en)
*
|
2003-12-05 |
2006-07-04 |
New Chapter, Inc. |
Methods for treating prostatic intraepithelial neoplasia with herbal compositions
|
WO2005070006A2
(en)
*
|
2004-01-22 |
2005-08-04 |
Nitromed, Inc. |
Nitrosated and/or nitrosylated compounds, compositions and methods of use
|
BRPI0506994A
(pt)
|
2004-01-22 |
2007-07-03 |
Pfizer |
derivados de triazol que inibem a atividade antagonista da vasopressina
|
US7521473B2
(en)
*
|
2004-02-25 |
2009-04-21 |
Wyeth |
Inhibitors of protein tyrosine phosphatase 1B
|
WO2005081960A2
(en)
*
|
2004-02-25 |
2005-09-09 |
Wyeth |
Inhibitors of protein tyrosine phosphatase 1b
|
ES2338344T3
(es)
*
|
2004-04-07 |
2010-05-06 |
Rinat Neuroscience Corporation |
Procedimiento de tratamiento del dolor de cancer de hueso mediante la administracion de una antagonista del factor de crecimiento neuronal.
|
MXPA06012510A
(es)
*
|
2004-04-28 |
2006-12-15 |
Pfizer |
Derivados de 3-heterociclil-4-fenil-triazol como inhibidores del receptor de vasopresina via.
|
GB0410121D0
(en)
*
|
2004-05-06 |
2004-06-09 |
Glaxo Group Ltd |
Compounds
|
US7507823B2
(en)
*
|
2004-05-06 |
2009-03-24 |
Bristol-Myers Squibb Company |
Process of making aripiprazole particles
|
WO2005120584A2
(en)
*
|
2004-06-03 |
2005-12-22 |
The Trustees Of Columbia University In The City Of New York |
Radiolabeled arylsulfonyl compounds and uses thereof
|
EP1604666A1
(de)
|
2004-06-08 |
2005-12-14 |
Euro-Celtique S.A. |
Opioide zur Behandlung der chronischen obstruktiven Lungenkrankheit
|
EP1765830B1
(de)
|
2004-07-01 |
2010-09-22 |
Merck Sharp & Dohme Corp. |
Inhibitoren von mitotischem kinesin
|
ES2257929B1
(es)
*
|
2004-07-16 |
2007-05-01 |
Laboratorios Del Dr. Esteve, S.A. |
Derivados de pirazolina, procedimiento para su obtencion y utilizacion de los mismos como agentes terapeuticos.
|
JP2008506768A
(ja)
*
|
2004-07-22 |
2008-03-06 |
ファルマシア コーポレーション |
Cox−2選択的阻害剤とltb4受容体アンタゴニストを組み合わせて用いる炎症および疼痛を治療するための組成物
|
US20080096927A1
(en)
|
2004-08-24 |
2008-04-24 |
Simon Thomas J |
Combination Therapy for Treating Cyclooxygenase-2 Mediated Diseases or Conditions in Patients at Risk of Thrombotic Cardiovascular Events
|
US7622142B2
(en)
*
|
2004-09-14 |
2009-11-24 |
New Chapter Inc. |
Methods for treating glioblastoma with herbal compositions
|
US20060064142A1
(en)
*
|
2004-09-17 |
2006-03-23 |
Cardiac Pacemakers, Inc. |
Systems and methods for deriving relative physiologic measurements using an implanted sensor device
|
WO2006041855A2
(en)
|
2004-10-04 |
2006-04-20 |
Nitromed, Inc. |
Compositions and methods using apocynin compounds and nitric oxide donors
|
EP1809759B1
(de)
|
2004-10-06 |
2013-09-11 |
The Brigham And Women's Hospital, Inc. |
Relevanz erzielter niveaus von markern für systemische entzündung nach behandlung
|
EP1814535A4
(de)
*
|
2004-11-08 |
2008-06-04 |
Nitromed Inc |
Nitrosierte und nitrosylierte verbindungen, zusammensetzungen und verfahren zur behandlung von augenkrankheiten
|
US20080275093A1
(en)
*
|
2004-11-15 |
2008-11-06 |
Nitromed, Inc. |
Diuretic Compounds Comprising Heterocyclic Nitric Oxide Donor Groups, Compositions and Methods of Use
|
ATE424386T1
(de)
|
2004-12-23 |
2009-03-15 |
Glaxo Group Ltd |
Pyridin-verbindungen für die behandlung von prostaglandin-vermittelten krankheiten
|
RU2401125C2
(ru)
*
|
2004-12-27 |
2010-10-10 |
Эйсай Ар Энд Ди Менеджмент Ко., Лтд. |
Способ стабилизации лекарственного средства против деменции
|
WO2006078995A1
(en)
*
|
2005-01-21 |
2006-07-27 |
Nitromed, Inc. |
Cardiovascular compounds comprising heterocyclic nitric oxide donor group compositions and methods of use
|
AU2006210952B2
(en)
*
|
2005-01-31 |
2011-08-04 |
Mylan Laboratories, Inc. |
Pharmaceutical composition comprising hydroxylated nebivolol
|
JP2008530226A
(ja)
*
|
2005-02-16 |
2008-08-07 |
ニトロメッド インコーポレーティッド |
抗微生物化合物の有機酸化窒素供与体塩、組成物、および使用法
|
US7521435B2
(en)
*
|
2005-02-18 |
2009-04-21 |
Pharma Diagnostics, N.V. |
Silicon containing compounds having selective COX-2 inhibitory activity and methods of making and using the same
|
WO2006093864A1
(en)
*
|
2005-02-28 |
2006-09-08 |
Nitromed, Inc. |
Cardiovascular compounds comprising nitric oxide enhancing groups, compositions and methods of use
|
EP1702558A1
(de)
|
2005-02-28 |
2006-09-20 |
Euro-Celtique S.A. |
Verfahren und Vorrichtung zur Darmtätigkeitserfassung
|
JP2008533031A
(ja)
*
|
2005-03-09 |
2008-08-21 |
ニトロメッド インコーポレーティッド |
アンギオテンシンiiアンタゴニストの有機酸化窒素増強塩、組成物および使用法
|
WO2006110918A1
(en)
*
|
2005-04-13 |
2006-10-19 |
Ambit Biosciences Corporation |
Pyrrole compounds and uses thereof
|
BRPI0608780A2
(pt)
*
|
2005-04-28 |
2010-11-09 |
Eisai R&D Man Co Ltd |
composição contendo fármaco anti-demência
|
WO2006121887A2
(en)
*
|
2005-05-05 |
2006-11-16 |
Cook Biotech Incorporated |
Implantable materials and methods for inhibiting tissue adhesion formation
|
WO2006123182A2
(en)
|
2005-05-17 |
2006-11-23 |
Merck Sharp & Dohme Limited |
Cyclohexyl sulphones for treatment of cancer
|
US20080234252A1
(en)
*
|
2005-05-18 |
2008-09-25 |
Pfizer Inc |
Compounds Useful in Therapy
|
US20090048219A1
(en)
*
|
2005-05-23 |
2009-02-19 |
Nitromed Inc. |
Organic nitric oxide donor salts of nonsteroidal antiinflammatory compounds, compositions and methods of use
|
EP2808015A1
(de)
|
2005-05-31 |
2014-12-03 |
Mylan Laboratories, Inc |
Zusammensetzungen mit Nebivolol
|
US20090018091A1
(en)
*
|
2005-08-02 |
2009-01-15 |
Nitromed, Inc. |
Nitric Oxide Enhancing Antimicrobial Compounds, Compositions and Methods of Use
|
PE20070335A1
(es)
|
2005-08-30 |
2007-04-21 |
Novartis Ag |
Benzimidazoles sustituidos y metodos para su preparacion
|
EP1942909A4
(de)
*
|
2005-10-04 |
2010-01-06 |
Nitromed Inc |
Verfahren zur behandlung von atemwegserkrankungen
|
US8119358B2
(en)
|
2005-10-11 |
2012-02-21 |
Tethys Bioscience, Inc. |
Diabetes-related biomarkers and methods of use thereof
|
JP2009514851A
(ja)
|
2005-11-08 |
2009-04-09 |
ランバクシー ラボラトリーズ リミテッド |
(3r,5r)−7−[2−(4−フルオロフェニル)−5−イソプロピル−3−フェニル−4−[(4−ヒドロキシメチルフェニルアミノ)カルボニル]−ピロール−1−イル]−3,5−ジヒドロキシ−ヘプタン酸ヘミカルシウム塩の製法
|
WO2007059311A2
(en)
*
|
2005-11-16 |
2007-05-24 |
Nitromed, Inc. |
Furoxan compounds, compositions and methods of use
|
TW200735866A
(en)
|
2005-11-18 |
2007-10-01 |
Synta Pharmaceuticals Corp |
Compounds for the treatment of proliferative disorders
|
EP1968584A2
(de)
*
|
2005-12-20 |
2008-09-17 |
Nitromed, Inc. |
Stickoxid-verstärkende glutaminsäure-verbindungen, zusammensetzungen und anwendungsverfahren
|
US20080293702A1
(en)
*
|
2005-12-22 |
2008-11-27 |
Nitromed, Inc. |
Nitric Oxide Enhancing Pyruvate Compounds, Compositions and Methods of Use
|
US20090062302A1
(en)
|
2006-01-24 |
2009-03-05 |
Buser-Doepner Carolyn A |
Jak2 Tyrosine Kinase Inhibition
|
GB0603041D0
(en)
|
2006-02-15 |
2006-03-29 |
Angeletti P Ist Richerche Bio |
Therapeutic compounds
|
PL2001496T3
(pl)
|
2006-03-15 |
2017-10-31 |
Brigham & Womens Hospital Inc |
Zastosowanie gelsoliny do diagnozowania i leczenia chorób zapalnych
|
AU2007243765A1
(en)
*
|
2006-03-29 |
2007-11-08 |
Nicox S.A. |
Nitric oxide enhancing prostaglandin compounds, compositions and methods of use
|
ES2654847T3
(es)
|
2006-04-19 |
2018-02-15 |
Novartis Ag |
Compuestos de benzoxazol y benzotiazol sustituidos en 6-O y métodos para inhibir la señalización CSF-1R
|
EP2924440A3
(de)
|
2006-06-07 |
2016-03-09 |
Health Diagnostic Laboratory, Inc. |
Mit arteriovaskulären ereignissen assoziierte marker und verfahren zur verwendung davon
|
HUE032156T2
(en)
|
2006-06-19 |
2017-09-28 |
Alpharma Pharmaceuticals Llc |
Pharmaceutical preparations
|
US8128460B2
(en)
*
|
2006-09-14 |
2012-03-06 |
The Material Works, Ltd. |
Method of producing rust inhibitive sheet metal through scale removal with a slurry blasting descaling cell
|
WO2008039327A2
(en)
|
2006-09-22 |
2008-04-03 |
Merck & Co., Inc. |
Method of treatment using fatty acid synthesis inhibitors
|
US20080208179A1
(en)
*
|
2006-10-26 |
2008-08-28 |
Reliant Technologies, Inc. |
Methods of increasing skin permeability by treatment with electromagnetic radiation
|
US8513329B2
(en)
|
2006-10-31 |
2013-08-20 |
Bio-Tec Environmental, Llc |
Chemical additives to make polymeric materials biodegradable
|
CN101589097B
(zh)
|
2006-10-31 |
2014-01-08 |
生物科技环境公司 |
用于使聚合物材料生物可降解的化学添加剂
|
US20110218176A1
(en)
|
2006-11-01 |
2011-09-08 |
Barbara Brooke Jennings-Spring |
Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
|
UA94979C2
(uk)
|
2006-12-22 |
2011-06-25 |
Рекордати Айеленд Лимитед |
КОМБІНОВАНА ТЕРАПІЯ ПОРУШЕНЬ НИЖНІХ СЕЧОВИВІДНИХ ШЛЯХІВ ЛІГАНДАМИ α2δ І НПЗП
|
AU2008204380B2
(en)
|
2007-01-10 |
2013-08-15 |
Msd Italia S.R.L. |
Amide substituted indazoles as poly(ADP-ribose)polymerase (PARP) inhibitors
|
US20100111858A1
(en)
*
|
2007-01-19 |
2010-05-06 |
Howard Carol P |
Diangostic and Therapeutic Cyclooxygenase-2 Binding Ligands
|
CN101679266B
(zh)
|
2007-03-01 |
2015-05-06 |
诺华股份有限公司 |
Pim激酶抑制剂及其应用方法
|
GB0704407D0
(en)
|
2007-03-07 |
2007-04-18 |
Glaxo Group Ltd |
Compounds
|
BRPI0810409A2
(pt)
|
2007-04-18 |
2015-02-18 |
Thethys Bioscience Inc |
Biomarcadores relacionados ao diabetes e métodos de uso destes
|
BRPI0812159A2
(pt)
|
2007-05-21 |
2017-05-02 |
Novartis Ag |
inibidores de csf-1r, composições e métodos de uso
|
US8389553B2
(en)
|
2007-06-27 |
2013-03-05 |
Merck Sharp & Dohme Corp. |
4-carboxybenzylamino derivatives as histone deacetylase inhibitors
|
MX2010000465A
(es)
|
2007-07-12 |
2010-08-30 |
Tragara Pharmaceuticals Inc |
Metodos y composiciones para el tratamiento de cancer, tumores y alteraciones relacionadas con tumores.
|
US7943658B2
(en)
*
|
2007-07-23 |
2011-05-17 |
Bristol-Myers Squibb Company |
Indole indane amide compounds useful as CB2 agonists and method
|
EP2200607A4
(de)
|
2007-09-10 |
2012-02-22 |
Calcimedica Inc |
Verbindungen als modulatoren von intrazellulärem calcium
|
US8623418B2
(en)
|
2007-12-17 |
2014-01-07 |
Alpharma Pharmaceuticals Llc |
Pharmaceutical composition
|
JP2011515343A
(ja)
|
2008-03-03 |
2011-05-19 |
タイガー ファーマテック |
チロシンキナーゼ阻害薬
|
GB2460915B
(en)
|
2008-06-16 |
2011-05-25 |
Biovascular Inc |
Controlled release compositions of agents that reduce circulating levels of platelets and methods therefor
|
GB0813142D0
(en)
|
2008-07-17 |
2008-08-27 |
Glaxo Group Ltd |
Novel compounds
|
GB0813144D0
(en)
|
2008-07-17 |
2008-08-27 |
Glaxo Group Ltd |
Novel compounds
|
BRPI0917719A2
(pt)
|
2008-08-27 |
2019-11-19 |
Calcimedica Inc |
compostos que modulam cálcio intracelular
|
EP2177215A1
(de)
|
2008-10-17 |
2010-04-21 |
Laboratorios Del. Dr. Esteve, S.A. |
Co-Kristalle von Tramadol und NSARs
|
CN101429181A
(zh)
*
|
2008-12-18 |
2009-05-13 |
毛近隆 |
对羟基苯丙烯酸衍生物及其应用
|
US20100160351A1
(en)
*
|
2008-12-19 |
2010-06-24 |
Nuon Therapeutics, Inc. |
Pharmaceutical compositions and methods for treating hyperuricemia and related disorders
|
WO2010071865A1
(en)
|
2008-12-19 |
2010-06-24 |
Nuon Therapeutics, Inc. |
Pharmaceutical compositions and methods for treating hyperuricemia and related disorders
|
GB0903493D0
(en)
|
2009-02-27 |
2009-04-08 |
Vantia Ltd |
New compounds
|
CA2754853C
(en)
|
2009-03-10 |
2015-04-28 |
Euro-Celtique S.A. |
Immediate release pharmaceutical compositions comprising oxycodone and naloxone
|
WO2011012622A1
(en)
|
2009-07-30 |
2011-02-03 |
Glaxo Group Limited |
Benzoxazinone derivatives for the treatment of glytl mediated disorders
|
WO2011023753A1
(en)
|
2009-08-27 |
2011-03-03 |
Glaxo Group Limited |
Benzoxazine derivatives as glycine transport inhibitors
|
WO2011032175A1
(en)
|
2009-09-14 |
2011-03-17 |
Nuon Therapeutics, Inc. |
Combination formulations of tranilast and allopurinol and methods related thereto
|
BR112012008849A2
(pt)
|
2009-10-14 |
2015-09-22 |
Schering Corp |
composto, composição farmacêutica, e, uso de um composto
|
US10668060B2
(en)
|
2009-12-10 |
2020-06-02 |
Collegium Pharmaceutical, Inc. |
Tamper-resistant pharmaceutical compositions of opioids and other drugs
|
WO2011075478A1
(en)
|
2009-12-16 |
2011-06-23 |
N30 Pharmaceuticals, Llc |
Novel thiophene inhibitors of s-nitrosoglutathione reductase
|
GB201000685D0
(en)
|
2010-01-15 |
2010-03-03 |
Glaxo Group Ltd |
Novel compounds
|
JP2013518618A
(ja)
|
2010-02-01 |
2013-05-23 |
ザ・ホスピタル・フォー・シック・チルドレン |
再狭窄を治療および予防するための遠隔虚血コンディショニング
|
SG184353A1
(en)
|
2010-03-31 |
2012-11-29 |
Hospital For Sick Children |
Use of remote ischemic conditioning to improve outcome after myocardial infarction
|
EP2563776B1
(de)
|
2010-04-27 |
2016-06-08 |
Calcimedica, Inc. |
Verbindungen als modulatoren von intrazellulärem calcium
|
US8754219B2
(en)
|
2010-04-27 |
2014-06-17 |
Calcimedica, Inc. |
Compounds that modulate intracellular calcium
|
GB201007789D0
(en)
|
2010-05-10 |
2010-06-23 |
Glaxo Group Ltd |
Novel Compound
|
GB201007791D0
(en)
|
2010-05-10 |
2010-06-23 |
Glaxo Group Ltd |
Novel compounds
|
EP2584903B1
(de)
|
2010-06-24 |
2018-10-24 |
Merck Sharp & Dohme Corp. |
Neue heterozyklische verbindungen als erk-hemmer
|
WO2012004604A1
(en)
|
2010-07-09 |
2012-01-12 |
Convergence Pharmaceuticals Limited |
Tetrazole compounds as calcium channel blockers
|
JP6043285B2
(ja)
|
2010-08-02 |
2016-12-14 |
サーナ・セラピューティクス・インコーポレイテッドSirna Therapeutics,Inc. |
低分子干渉核酸(siNA)を用いたカテニン(カドヘリン結合型タンパク質)β1(CTNNB1)遺伝子発現のRNA干渉媒介性阻害
|
HUE044815T2
(hu)
|
2010-08-17 |
2019-11-28 |
Sirna Therapeutics Inc |
Hepatitisz B vírus (HBV) génexpressziójának RNS-interferencia közvetített gátlása, rövid interferáló nukleinsav (SINS) alkalmazásával
|
PL3333188T3
(pl)
|
2010-08-19 |
2022-05-09 |
Zoetis Belgium S.A. |
Przeciwciała anty-ngf i ich zastosowanie
|
EP2608669B1
(de)
|
2010-08-23 |
2016-06-22 |
Merck Sharp & Dohme Corp. |
Neue pyrazolo-[1,5-a-]pyrimidinderivate als mtor-hemmer
|
MX337711B
(es)
|
2010-08-27 |
2016-03-15 |
Calcimedica Inc |
Compuestos que modulan el calcio intracelular.
|
EP2613782B1
(de)
|
2010-09-01 |
2016-11-02 |
Merck Sharp & Dohme Corp. |
Indazolderivate als erk-hemmer
|
WO2012036997A1
(en)
|
2010-09-16 |
2012-03-22 |
Schering Corporation |
Fused pyrazole derivatives as novel erk inhibitors
|
US9260471B2
(en)
|
2010-10-29 |
2016-02-16 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using short interfering nucleic acids (siNA)
|
WO2012087772A1
(en)
|
2010-12-21 |
2012-06-28 |
Schering Corporation |
Indazole derivatives useful as erk inhibitors
|
KR101572336B1
(ko)
|
2010-12-22 |
2015-11-26 |
퍼듀 퍼머 엘피 |
케이싱된 탬퍼 저항성 제어 방출 투여 형태
|
AU2011346758C1
(en)
|
2010-12-23 |
2015-09-03 |
Purdue Pharma L.P. |
Tamper resistant solid oral dosage forms
|
US8933132B2
(en)
|
2011-01-19 |
2015-01-13 |
Convergence Pharmaceuticals Limited |
Tricyclic substituted benzenesulfonamide piperazine derivatives as CAV2.2 calcium channel blockers
|
US20140045847A1
(en)
|
2011-04-21 |
2014-02-13 |
Piramal Enterprises Limited |
Crystalline form of a salt of a morpholino sulfonyl indole derivative and a process for its preparation
|
EP2710039B1
(de)
|
2011-05-20 |
2019-01-09 |
AlderBio Holdings LLC |
Anti-cgrp-zusammensetzungen und ihre verwendung
|
WO2013063214A1
(en)
|
2011-10-27 |
2013-05-02 |
Merck Sharp & Dohme Corp. |
Novel compounds that are erk inhibitors
|
WO2013066729A1
(en)
|
2011-10-31 |
2013-05-10 |
Merck Sharp & Dohme Corp. |
Aminopyrimidinones as interleukin receptor-associated kinase inhibitors
|
GB201122113D0
(en)
|
2011-12-22 |
2012-02-01 |
Convergence Pharmaceuticals |
Novel compounds
|
EP3919620A1
(de)
|
2012-05-02 |
2021-12-08 |
Sirna Therapeutics, Inc. |
Zusammensetzungen mit kurzer interferierender nukleinsäure (sina)
|
JP6377054B2
(ja)
|
2012-05-11 |
2018-08-22 |
リセット セラピューティークス, インコーポレイテッド |
クリプトクロム調節薬としてのカルバゾール含有スルホンアミド
|
JP6629069B2
(ja)
|
2012-06-06 |
2020-01-15 |
ゾエティス・エルエルシー |
イヌ化抗ngf抗体およびその方法
|
US9233979B2
(en)
|
2012-09-28 |
2016-01-12 |
Merck Sharp & Dohme Corp. |
Compounds that are ERK inhibitors
|
US9512116B2
(en)
|
2012-10-12 |
2016-12-06 |
Calcimedica, Inc. |
Compounds that modulate intracellular calcium
|
BR112015012295A8
(pt)
|
2012-11-28 |
2023-03-14 |
Merck Sharp & Dohme |
Uso de um inibidor de wee1, e, kit para identificar um paciente com câncer
|
BR112015013611A2
(pt)
|
2012-12-20 |
2017-11-14 |
Merck Sharp & Dohme |
composto, e, composição farmacêutica
|
EP2951180B1
(de)
|
2013-01-30 |
2018-05-02 |
Merck Sharp & Dohme Corp. |
2,6,7,8-substituierte purine als hdm2-inhibitoren
|
ES2851175T3
(es)
|
2013-02-05 |
2021-09-03 |
Purdue Pharma Lp |
Formulaciones farmacéuticas resistentes a manipulación
|
US20160024098A1
(en)
|
2013-03-15 |
2016-01-28 |
President And Fellows Of Harvard College |
Hybrid necroptosis inhibitors
|
US10751287B2
(en)
|
2013-03-15 |
2020-08-25 |
Purdue Pharma L.P. |
Tamper resistant pharmaceutical formulations
|
TWI634114B
(zh)
|
2013-05-08 |
2018-09-01 |
永恒生物科技公司 |
作為激酶抑制劑之呋喃酮化合物
|
EP3019171B1
(de)
|
2013-07-11 |
2018-09-05 |
Merck Sharp & Dohme Corp. |
Substituierte amidopyrazolhemmer von interleukinrezeptor-assoziierten kinasen (irak-4)
|
UA116567C2
(uk)
|
2013-07-23 |
2018-04-10 |
Євро-Селтік С.А. |
Комбінація оксикодону та налоксону для застосування в лікуванні болю у пацієнтів, які страждають від болю та захворювання, що призводить до дисбактеріозу кишечнику та/або підвищує ризик кишкової бактеріальної транслокації
|
EP3041938A1
(de)
|
2013-09-03 |
2016-07-13 |
Moderna Therapeutics, Inc. |
Kreisförmige polynukleotide
|
WO2015054283A1
(en)
|
2013-10-08 |
2015-04-16 |
Calcimedica, Inc. |
Compounds that modulate intracellular calcium
|
KR101446601B1
(ko)
*
|
2014-01-29 |
2014-10-07 |
크리스탈지노믹스(주) |
5-(4-(아미노설포닐)페닐)-2,2-디메틸-4-(3-플루오로페닐)-3(2h)-퓨라논을 포함하는 약학적 조성물 및 캡슐 제형
|
US10413520B2
(en)
|
2014-01-29 |
2019-09-17 |
Crystalgenomics, Inc. |
Oral pharmacological composition including 5-{4-(amino sulfonyl)phenyl}-2,2-dimethyl-4-(3-fluorophenyl)-3(2H)-furanone having crystalline structure with excellent stability
|
TWI690521B
(zh)
|
2014-04-07 |
2020-04-11 |
美商同步製藥公司 |
作為隱花色素調節劑之含有咔唑之醯胺類、胺基甲酸酯類及脲類
|
JO3589B1
(ar)
|
2014-08-06 |
2020-07-05 |
Novartis Ag |
مثبطات كيناز البروتين c وطرق استخداماتها
|
GB201417499D0
(en)
|
2014-10-03 |
2014-11-19 |
Convergence Pharmaceuticals |
Novel use
|
GB201417497D0
(en)
|
2014-10-03 |
2014-11-19 |
Convergence Pharmaceuticals |
Novel use
|
GB201417500D0
(en)
|
2014-10-03 |
2014-11-19 |
Convergence Pharmaceuticals |
Novel use
|
RU2563876C1
(ru)
*
|
2014-11-11 |
2015-09-27 |
Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Санкт-Петербургский государственный университет" (СПбГУ) |
Способ получения 2,2-диалкил-4,5-диарилфуран-3(2н)-онов
|
EP3268003B1
(de)
|
2015-03-12 |
2020-07-29 |
Merck Sharp & Dohme Corp. |
Thienopyrazininhibitoren der irak4-aktivität
|
WO2016144844A1
(en)
|
2015-03-12 |
2016-09-15 |
Merck Sharp & Dohme Corp. |
Carboxamide inhibitors of irak4 activity
|
US10329294B2
(en)
|
2015-03-12 |
2019-06-25 |
Merck Sharp & Dohme Corp. |
Pyrazolopyrimidine inhibitors of IRAK4 activity
|
EP3292213A1
(de)
|
2015-05-04 |
2018-03-14 |
Academisch Medisch Centrum |
Biomarker für den nachweis von aspirinunempfindlichkeit
|
CN109311977B
(zh)
|
2016-04-15 |
2022-06-14 |
H.伦德贝克公司 |
人源化的抗pacap抗体及其用途
|
WO2017222575A1
(en)
|
2016-06-23 |
2017-12-28 |
Collegium Pharmaceutical, Inc. |
Process of making more stable abuse-deterrent oral formulations
|
CN109475526A
(zh)
|
2016-07-21 |
2019-03-15 |
荷兰联合利华有限公司 |
用于治疗呼吸道感染的内酰胺
|
US11083706B2
(en)
|
2016-07-21 |
2021-08-10 |
Conopco, Inc. |
Lactams for use in the treatment of skin lesions
|
BR112019001127A2
(pt)
|
2016-07-21 |
2019-04-30 |
Unilever N.V. |
uso de lactama
|
WO2019094311A1
(en)
|
2017-11-08 |
2019-05-16 |
Merck Sharp & Dohme Corp. |
Prmt5 inhibitors
|
EP3765499A1
(de)
|
2018-03-12 |
2021-01-20 |
Zoetis Services LLC |
Anti-ngf-antikörper und verfahren dafür
|
WO2020033282A1
(en)
|
2018-08-07 |
2020-02-13 |
Merck Sharp & Dohme Corp. |
Prmt5 inhibitors
|
EP3833667B1
(de)
|
2018-08-07 |
2024-03-13 |
Merck Sharp & Dohme LLC |
Prmt5-inhibitoren
|
US20220031631A1
(en)
|
2018-09-19 |
2022-02-03 |
Modernatx, Inc. |
High-purity peg lipids and uses thereof
|
CA3113025A1
(en)
|
2018-09-19 |
2020-03-26 |
Modernatx, Inc. |
Peg lipids and uses thereof
|
EP3883562A4
(de)
|
2018-11-21 |
2022-08-03 |
Tremeau Pharmaceuticals, Inc. |
Gereinigte formen von rofecoxib, verfahren zur herstellung und verwendung
|
CN110452199B
(zh)
*
|
2019-09-03 |
2021-03-30 |
山东鲁抗舍里乐药业有限公司 |
一种非罗考昔的制备方法
|
CN110452198B
(zh)
*
|
2019-09-03 |
2021-03-26 |
山东鲁抗舍里乐药业有限公司 |
一种非罗考昔的制备方法
|
US10945992B1
(en)
|
2019-11-13 |
2021-03-16 |
Tremeau Pharmaceuticals, Inc. |
Dosage forms of rofecoxib and related methods
|
US20230108452A1
(en)
|
2019-12-17 |
2023-04-06 |
Merck Sharp & Dohme Llc |
Prmt5 inhibitors
|
CN114014824B
(zh)
*
|
2020-12-09 |
2023-06-13 |
上海科技大学 |
一种杂环化合物的应用
|
EP4306520A1
(de)
*
|
2021-03-11 |
2024-01-17 |
Medshine Discovery Inc. |
Thiophenverbindung und anwendung davon
|
IL305573A
(en)
|
2021-03-15 |
2023-10-01 |
Saul Yedgar |
Hyaluronic acid conjugated with dipalmitoyl phosphatidyl ethanolamine in combination with non-steroidal anti-inflammatory drugs (NSAIDs) for the treatment or suppression of inflammatory diseases
|
US11161833B1
(en)
|
2021-04-09 |
2021-11-02 |
Tremeau Pharmaceuticals, Inc. |
Deuterated etoricoxib, methods of manufacture, and use thereof
|
CN117813325A
(zh)
|
2021-08-27 |
2024-04-02 |
H.隆德贝克有限公司 |
使用抗cgrp抗体治疗丛集性头痛
|